Therefore, since acetylation of SRBPs is considered a crucial event for the pathogenesis of metabolic disorders64–66 its deacetylation through SIRT1 targeting could be useful in the treatment of T2D. Here, SIRT1 is linked to type 2 diabetes mellitus.